JP2018535224A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535224A5
JP2018535224A5 JP2018526543A JP2018526543A JP2018535224A5 JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5 JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nanoparticle
composition according
patient
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535224A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/062816 external-priority patent/WO2017087825A1/en
Publication of JP2018535224A publication Critical patent/JP2018535224A/ja
Publication of JP2018535224A5 publication Critical patent/JP2018535224A5/ja
Pending legal-status Critical Current

Links

JP2018526543A 2015-11-19 2016-11-18 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤 Pending JP2018535224A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257569P 2015-11-19 2015-11-19
US62/257,569 2015-11-19
PCT/US2016/062816 WO2017087825A1 (en) 2015-11-19 2016-11-18 Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations

Publications (2)

Publication Number Publication Date
JP2018535224A JP2018535224A (ja) 2018-11-29
JP2018535224A5 true JP2018535224A5 (https=) 2019-12-26

Family

ID=58717907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526543A Pending JP2018535224A (ja) 2015-11-19 2016-11-18 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤

Country Status (12)

Country Link
US (1) US20180339024A1 (https=)
EP (1) EP3377080B1 (https=)
JP (1) JP2018535224A (https=)
KR (1) KR20180081608A (https=)
CN (1) CN108883150A (https=)
AU (1) AU2016358125A1 (https=)
BR (1) BR112018010052A2 (https=)
CA (1) CA3005284A1 (https=)
IL (1) IL259376A (https=)
MX (1) MX2018006194A (https=)
SG (2) SG10202004259PA (https=)
WO (1) WO2017087825A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021056B1 (pt) 2017-04-06 2022-11-22 Sustain Holdings, Llc Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
US20210113654A1 (en) * 2018-05-31 2021-04-22 Yale University Methods and Compositions to Alleviate Vascular Permeability
AU2020248438A1 (en) 2019-03-26 2021-10-28 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP3958889B1 (en) 2019-04-22 2025-01-08 Sustain Holdings, LLC Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
WO2021178949A1 (en) * 2020-03-06 2021-09-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
WO1996002561A1 (en) 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1696038B1 (en) 1999-05-05 2010-06-02 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
AU4761100A (en) 1999-05-26 2000-12-18 Kalle Saksela Methods and materials for generating sh3 domains with tailored binding properties
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20040132094A1 (en) 2000-12-13 2004-07-08 Michael Etzerodt Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
CA2501295A1 (en) 2002-10-02 2004-04-15 Jack Nguyen Methods of generating and screening for proteases with altered specificity
DK1587907T3 (da) 2003-01-07 2011-04-04 Dyax Corp Kunitz-domænebibliotek
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
WO2008085828A2 (en) * 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
WO2010132879A2 (en) * 2009-05-15 2010-11-18 The Johns Hopkins University Multicomponent degradable cationic polymers
US20110143993A1 (en) * 2009-12-15 2011-06-16 The Brigham And Women's Hospital, Inc. Endothelial basement membrane targeting peptide ligands
EP2649095B1 (en) 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
US9309286B2 (en) * 2011-08-17 2016-04-12 Tufts Medical Center Compositions and methods for augmenting permeability barriers
CA2858115A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
WO2014018018A1 (en) * 2012-07-24 2014-01-30 Morehouse School Of Medicine Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
EP3733244A1 (en) * 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2018535224A5 (https=)
Yasmin et al. Novel drug delivery systems for inflammatory bowel disease
Du et al. Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation
Khan et al. PLGA nanoparticles and their versatile role in anticancer drug delivery
Wu et al. Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases
Hu et al. Tumor microenvironment-mediated construction and deconstruction of extracellular drug-delivery depots
CN109890420B (zh) 用于递送治疗剂的血小板组合物和方法
Cabeza et al. Nanoparticles in colorectal cancer therapy: latest in vivo assays, clinical trials, and patents
Liu et al. Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage
Sarvaiya et al. Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery
JP6343147B2 (ja) 狭窄病変および血栓溶解療法のための剪断による制御放出
Zou et al. Targeted delivery of nano-PTX to the brain tumor-associated macrophages
US20170333365A1 (en) Core-shell particle formulation for delivering multiple therapeutic agents
Pinto et al. Targeted brain delivery nanoparticles for malignant gliomas
JP2016521712A5 (https=)
CN102970864A (zh) 纳米颗粒药物组合物
Guo et al. Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy
Morales-Orue et al. Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies
Zhao et al. Teaching new tricks to old dogs: A review of drug repositioning of disulfiram for cancer nanomedicine
Mishra et al. Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles
Panchangam et al. Engineered nanoparticles for the delivery of anticancer therapeutics
Joshi et al. Inhibition of cancer cell metastasis by nanotherapeutics: current achievements and future trends
Su et al. Eudragit S100 coated nanodiamond-based nanoparticles as an oral chemo-photothermal delivery system for local treatment of colon cancer
Yang et al. Intravenous administration of scutellarin nanoparticles augments the protective effect against cerebral ischemia–reperfusion injury in rats
Alavi et al. Nanocarrier system for increasing the therapeutic efficacy of oxaliplatin